Halozyme Therapeutics (NASDAQ:HALO) Stock Rating Raised to Strong-Buy at Zacks Research

Zacks Research upgraded shares of Halozyme Therapeutics (NASDAQ:HALO) from a hold rating to a strong-buy rating in a research note issued to investors on Tuesday,Zacks reports.

Several other analysts have also weighed in on HALO. Citizens Jmp upped their target price on Halozyme Therapeutics from $92.00 to $93.00 and gave the company a “market outperform” rating in a report on Friday, August 7th. JPMorgan Chase & Co. raised their price target on Halozyme Therapeutics from $70.00 to $78.00 and gave the company a “neutral” rating in a research report on Thursday, October 8th. HC Wainwright lifted their price target on Halozyme Therapeutics from $115.00 to $130.00 and gave the stock a “buy” rating in a research note on Wednesday, October 7th. Leerink Partners upgraded shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and boosted their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. Finally, Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Halozyme Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $96.50.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO opened at $116.82 on Tuesday. The firm has a market capitalization of $13.26 billion, a price-to-earnings ratio of 34.87, a price-to-earnings-growth ratio of 0.41 and a beta of 0.88. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The business’s 50 day simple moving average is $107.97 and its 200-day simple moving average is $84.24. Halozyme Therapeutics has a 12 month low of $61.22 and a 12 month high of $119.21.

Halozyme Therapeutics (NASDAQ:HALO) last released its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.49. The firm had revenue of $481.00 million during the quarter, compared to the consensus estimate of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. Halozyme Therapeutics’s quarterly revenue was up 47.7% on a year-over-year basis. During the same period last year, the business posted $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. As a group, equities analysts forecast that Halozyme Therapeutics will post 8.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Halozyme Therapeutics

In other news, Director Matthew L. Posard sold 5,230 shares of the business’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $108.54, for a total value of $567,664.20. Following the completion of the transaction, the director directly owned 53,609 shares of the company’s stock, valued at $5,818,720.86. The trade was a 8.89% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bernadette Connaughton sold 1,626 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $102.80, for a total value of $167,152.80. Following the completion of the transaction, the director directly owned 40,418 shares of the company’s stock, valued at approximately $4,154,970.40. This trade represents a 3.87% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 125,852 shares of company stock worth $13,538,046. 2.50% of the stock is owned by insiders.

Institutional Trading of Halozyme Therapeutics

A number of large investors have recently made changes to their positions in the stock. Congress Asset Management Co. raised its position in shares of Halozyme Therapeutics by 85.6% in the 3rd quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after buying an additional 1,052,509 shares during the period. Bank of America Corp DE purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $214,504,000. William Blair Investment Management LLC purchased a new stake in Halozyme Therapeutics during the second quarter valued at about $196,540,000. Royal London Asset Management Ltd. grew its position in Halozyme Therapeutics by 12.4% during the second quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after acquiring an additional 200,262 shares during the period. Finally, Jupiter Topco LLC acquired a new stake in Halozyme Therapeutics during the second quarter worth about $105,570,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Analyst sentiment strengthened. Zacks Research upgraded Halozyme from “Hold” to “Strong Buy,” while TD Cowen raised its price target from $105 to $130 and reaffirmed a Buy rating. The new target implies additional upside from the current trading level. TD Cowen Forecasts Strong Price Appreciation for Halozyme Therapeutics
• Positive Sentiment: Roche’s Tecentriq Hybreza approval expanded a potential royalty opportunity. The FDA approval for a new stage III dMMR colon cancer indication broadens the commercial market for a Roche product using Halozyme’s drug-delivery technology. Strong clinical results could support future demand and royalty revenue. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment
• Positive Sentiment: A European patent ruling reduced competitive concerns. A Dutch court injunction blocking manufacture and sale of Merck’s Keytruda SC in several European markets supports Halozyme’s intellectual-property position and may protect the outlook for its subcutaneous drug-delivery platform. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment
• Positive Sentiment: Growth and earnings expectations remain supportive. Zacks highlighted Halozyme’s growth characteristics, while another report pointed to the company’s history of earnings surprises and potential for another beat in its next quarterly report.
• Neutral Sentiment: The stock is trading near its one-year high. Momentum is strong, with the shares well above their 50-day and 200-day moving averages, but the elevated valuation increases sensitivity to any earnings or guidance disappointment.
• Negative Sentiment: Insider selling is a risk signal. Quiver Quantitative reported 67 insider sales and no purchases over the past six months, including substantial sales by CEO Helen Torley. Institutional positioning was mixed, with some funds adding shares while others reduced or exited holdings. Halozyme gains as partner-drug approval, patent win, and bullish analyst call lift sentiment

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses recombinant human hyaluronidase to temporarily modify tissue beneath the skin, allowing certain drugs and biologics that are traditionally delivered by intravenous infusion to be administered by subcutaneous injection.

Halozyme licenses its technology to pharmaceutical and biotechnology companies, which incorporate it into their own therapies.